Skip to content
DataLookout
Menu

City of Hope Medical Center clinical trial pipeline

Get alerts when City of Hope Medical Center's trials change
Data updated daily from ClinicalTrials.gov, last refresh 2026-11-19

What changed in the last 30 days

82 trials changed in the last 30 days: 2 stopped, 48 with notable changes, 32 with minor changes only.

  1. Notable: Pembrolizumab and Blinatumomab · Recurrent or Refractory Acute Lymphoblastic Leukemia Results posted: Nov 17, 2026 City of Hope Medical CenterPhase 1/2 NCT03512405
  2. Notable: Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant · High-Risk Acute Leukemia or Myelodysplastic Syndrome Trial status changed: Suspended → Active, Not Recruiting City of Hope Medical CenterPhase 1 NCT03494569
  3. Notable: Genetically Engineered Cells (BAFFR-CAR T Cells) · Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Lymphoblastic Lymphoma Recruitment opened City of Hope Medical CenterPhase 1 NCT07758673
  4. Minor: Lysozyme Goat Milk · Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant Study completion pushed from Oct 27, 2026 to Mar 23, 2027 City of Hope Medical CenterPhase 1 NCT04177004
  5. Minor: HOPE-Genomics Intervention for the Improvement of Cancer Patient Knowledge of Genomics Study completion pushed from Oct 1, 2026 to Jan 1, 2027 City of Hope Medical CenterNot applicable NCT04905082
  6. Notable: Scheduled Meditation for Improving Postoperative Outcomes in Patients Undergoing Pancreatectomy Primary and study completion pushed from Nov 25, 2026 to Nov 25, 2027 City of Hope Medical CenterNot applicable NCT07608458
  7. Notable: Enasidenib (AG-221) Maintenance Post Allogeneic HCT · IDH2 Mutation Trial status changed: Suspended → Active, Not Recruiting City of Hope Medical CenterPhase 2 NCT03728335
  8. Notable: CS1-CAR T Therapy Following Chemotherapy · Relapsed or Refractory CS1 Positive Multiple Myeloma Trial status changed: Suspended → Active, Not Recruiting City of Hope Medical CenterPhase 1 NCT03710421
  9. Notable: Intraoperative Neuromonitoring of Sacral Reflexes to Predict Post Operative Function in Patients Undergoing Sacrectomy for Pelvic Bone Malignancy or Patients Undergoing Spinal Procedures Without Sacral Root Involvement Recruitment opened City of Hope Medical CenterNot applicable NCT07707024
  10. Minor: Leflunomide, Pomalidomide, and Dexamethasone · Relapsed or Refractory Multiple Myeloma Enrollment closed, study ongoing City of Hope Medical CenterPhase 2 NCT04508790
  11. Minor: Pevonedistat and Ibrutinib · Relapsed or Refractory CLL or Non-Hodgkin Lymphoma Trial completed City of Hope Medical CenterPhase 1 NCT03479268
  12. Minor: Gemcitabine and Leflunomide · Advanced Unresectable Pancreatic Cancer Enrollment closed, study ongoing City of Hope Medical CenterPhase 1 NCT06454383
  13. Notable: Stereotactic Body Radiation Therapy and FES PET/CT Imaging · Oligoprogressive Estrogen Receptor Positive Metastatic Breast Cancer Primary and study completion pushed from Oct 29, 2026 to Oct 29, 2027 City of Hope Medical CenterPhase 2 NCT06260033
  14. Notable: Leflunomide · High-Risk Smoldering Multiple Myeloma Primary and study completion pushed from Nov 10, 2026 to Oct 13, 2027 City of Hope Medical CenterEarly Phase 1 NCT04370483
  15. Notable: CD33-CAR T Cell Therapy · Recurrent or Refractory Acute Myeloid Leukemia Primary and study completion pushed from Sep 3, 2028 to Sep 3, 2031 City of Hope Medical CenterPhase 1 NCT05672147
  16. Notable: Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil · Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant Primary and study completion pushed from May 25, 2027 to Nov 5, 2028 City of Hope Medical CenterPhase 1 NCT06996119
  17. Notable: PSCA-Targeting CAR-T Cells Plus or Minus Radiation · PSCA+ Metastatic Castration-Resistant Prostate Cancer Primary and study completion pushed from Nov 11, 2028 to Nov 11, 2029 City of Hope Medical CenterPhase 1 NCT05805371
  18. Notable: Ruxolitinib in Combination With CHOP Chemotherapy · Untreated Nodal T-Follicular Helper Cell Lymphomas Primary and study completion pushed from Mar 31, 2027 to Dec 10, 2027 City of Hope Medical CenterPhase 1 NCT07278856
  19. Minor: Mezigdomide (CC-92480) Post Idecabtagene Vicleucel · Relapsed Multiple Myeloma Enrollment closed, study ongoing City of Hope Medical CenterPhase 1 NCT06048250
  20. Minor: Radiotherapy in Combination With Atezolizumab in Locally Advanced Borderline Resectable or Unresectable Cutaneous SCC Enrollment closed, study ongoing City of Hope Medical CenterPhase 1 NCT05085496
  • Stopped: terminated, suspended or withdrawn
  • Notable: the plan changed
  • Minor: routine updates

New trial filings, last 30 days

First postedTrialPhaseStatus
2026-11-09 NCT07926893 Lenalidomide and Cosibelimab for the Treatment of Relapsed/Refractory Mycosis Fungoides… Phase 1 Not Yet Recruiting
2026-11-09 NCT07926906 Removing the Planning Tumor Volume From Radiation Therapy for the Treatment of Head and… Not Yet Recruiting
2026-11-03 NCT07914166 Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia… Phase 1 Not Yet Recruiting

Active trials by phase

Early Phase 1
11
Phase 1
109
Phase 1/2
15
Phase 2
86
Phase 3
5
Phase 4
1
Not charted: 108 active trials with no phase listed on ClinicalTrials.gov (typically behavioural, device, procedure and observational studies).
Get alerts when City of Hope Medical Center's trials change
Status changes, date slips, and new filings: detected daily, delivered to your inbox.
Start monitoring free